文献速递慢阻肺

慢阻肺临床前模型的最新综述

Preclinical models of COPD: a state of the art review.
PubMed 文献 · Eur Respir J · 2026-10-09

该综述系统梳理了慢阻肺(COPD)的临床前模型,包括体内、离体和计算机模拟三大平台,指出尽管各模型已提供重要机制见解,但均无法完全再现COPD进展、共病、基因-环境交互及异质性临床内型的复杂性,并提出以表型驱动、跨平台整合的未来发展方向。

要点

  • 现有COPD临床前模型包括动物、离体肺切片/类器官/芯片及计算机模拟,各有局限。
  • 尚无疾病修饰治疗,需提升临床前模型的转化相关性。
  • 未来应整合人源数据、先进暴露平台与AI多组学,推动表型特异性治疗。

核心结论

  • 现有临床前模型均不能完全模拟COPD的异质性、进展、共病及基因-环境交互,未来需发展更整合、更人源化的建模系统。

研究设计与样本

  • 本文为最新综述,总结了体内(小/大动物、遗传与损伤模型、环境暴露)、离体(精密肺切片、类器官、共培养、肺芯片)及计算机模拟(气溶胶扩散与计算工具)等主要实验平台。

主要发现

  • 各实验平台均提供了重要机制见解,但无一能完全再现COPD进展、共病、基因-环境交互或异质性临床内型的复杂性。
  • 大型人群队列与单细胞/多组学研究为当前COPD模型的开发提供了信息。

关键数值与推荐

  • 提出了表型驱动的跨平台框架:由人类临床与组学数据提出假设,在体外和离体系统中验证,在表型特异性体内模型中评估,最终通过临床研究确认。

临床怎么用

  • 临床医生可关注该框架对未来表型特异性治疗开发及转化研究的指导意义。

局限性

  • 综述指出,现有模型均无法完全捕捉COPD的复杂性,未来需整合先进暴露平台与人工智能驱动的多组学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COPD is a progressive and heterogeneous condition characterised by varying combinations of emphysema, small airway disease, chronic bronchitis and exacerbations. Although multiple symptomatic therapies exist, no disease-modifying treatments are available. This gap highlights the need for improved preclinical models with greater translational relevance. Large human cohorts and single-cell/multi-omics studies have informed the development of current COPD models. We provide a state of the art review of the major experimental platforms: in vivo (small and large animals, genetic and injury models, environmental exposures), ex vivo (precision-cut lung slices, organoids, co-cultures, lung-on-a-chip systems) and in silico (aerosol dispersion and computational tools). While each approach has yielded important mechanistic insights, none fully captures the complexity of COPD progression, comorbidities, gene-environment interactions or heterogeneous clinical endotypes. Future progress will depend on the development of more integrated, human-relevant modelling systems, alongside advanced exposure platforms and artificial intelligence-driven multi-omics integration to identify biologically meaningful endotypes and speed the creation of phenotype-specific therapies. We propose a phenotype-driven, cross-platform framework in which hypotheses emerging from human clinical and omics data are validated in in vitro and ex vivo systems, evaluated in phenotype-specific in vivo models, and ultimately confirmed through clinical studies.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Polverino F, Benam KH, Cloonan SM, et al. Preclinical models of COPD: a state of the art review. Eur Respir J. 2026. PMID: 42562589. doi:10.1183/13993003.00289-2026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。